What else besides commodity oils and fats?

For over 40 years Oil World publications of Hamburg have provided business data on 17 commercial oils. These include 4 animal fats and 13 vegetable oils from 12 species. But natural oils are seldom optimum for their ultimate human use. This review refers briefly to the technological methods of modifying lipids and describes in more detail five biological procedures by which a wider range of lipids is being developed. These include the domestication of wild crops, the modification of existing crops by seed breeding and by genetic modification, the use of microbial lipids particularly as a source of PUFA, and the modification of triacylglycerol composition by lipase-mediated reaction.     

Microbial and algal oils: Do they have a future for biodiesel or as commodity oils?

We review the prospects of using yeasts and microalgae as sources of cheap oils that could be used for biodiesel. We conclude that yeast oils, the cheapest of the oils producible by heterotrophic microorganisms, are too expensive to be viable alternatives to the major commodity plant oils. Algal oils are similarly unlikely to be economic; the cheapest form of cultivation is in open ponds which then requires a robust, fast‐growing alga that can withstand adventitious predatory protozoa or contaminating bacteria and, at the same time, attain an oil content of at least 40% of the biomass. No such alga has yet been identified. However, we note that if the prices of the major plant oils and crude oil continue to rise in the future, as they have done over the past 12 months, then algal lipids might just become a realistic alternative within the next 10 to 15 years. Better prospects would, however, be to focus on algae as sources of polyunsaturated fatty acids.     

Stromal Interactions as Regulators of Tumor Growth and Therapeutic Response: A Potential Target for Photodynamic Therapy?

It has become increasingly widely recognized that the stroma plays several vital roles in tumor growth and development and that tumor-stroma interactions can in many cases account for poor therapeutic response. Inspired by an emerging body of literature, we consider the potential role of photodynamic therapy (PDT) in targeting interactions with stromal fibroblasts and mechanosensitive signaling with the extracellular matrix as a means to drive tumors toward a more therapeutically responsive state and synergize with other treatments. This concept is particularly relevant for cancer of the pancreas, which is characterized by tumors with a profoundly dense, rigid fibrous stroma. Here we introduce new in vitro systems to model interactions between pancreatic tumors and their mechanical microenvironment and restore signaling with stromal fibroblasts. Using one such model as a test bed it is shown here that PDT treatment is able to destroy fibroblasts in an in vitro 3D pancreatic tumor-fibroblast coculture. These results and the literature suggest the further development of PDT as a potential modality for stromal depletion.     

Citric acid: Inactivating agent for metals or acidic synergist in edible fats?

Oxidative stabilities of soybean oil and lard are improved by the addition of either sorbitol or citric acid. Sufficient sorbitol gives enough improvement in stability so that added citric acid gives no increased stability. Unless sorbitol acts as a neutral synergist, forms a powerful acidic synergist in trace amounts or a new antioxidant, the antioxidant activity of citric acid appears to come from its inactivating capacities for metals. Presented in part at the 125th American Chemical Society Meeting, Kansas City, Mo., March 24–April 1, 1954. This is a laboratory of the Northern Utilization Research and Development Division, Agricultural Research Service, U. S. Department of Agriculture.     

A New Route to Highly Stretchable and Soft Inorganic–Organic Hybrid Elastomers Using Polydimethylsiloxane as Crosslinker of Epoxidized Natural Rubber

Sulfur or peroxide crosslinking is the most common and conventional method to develop elastomeric materials. A new approach to crosslink epoxidized natural rubber (ENR) by aminopropyl terminated polydimethylsiloxane (AT-PDMS) is described, intending to develop a new kind of hybrid organic–inorganic elastomers. The curing reaction is accelerated by using hydroquinone as a catalyst. The formation of the hybrid structure is evident from the appearance of two glass transition temperatures, at −1 and −120 °C, for the ENR and PDMS phases, respectively. The curing reaction is found to be of first order with respect to amine concentration with the estimated activation energy of ≈62 kJ mol⁻¹. Comparing the mechanical properties to a typical ENR-sulfur system leads to the conclusion that the ENR/AT-PDMS hybrid structure is highly stretchable and soft, as demonstrated by its relatively higher strain at failure (up to ≈630%), and lower hardness and modulus values. The higher stretchability and soft nature of the material are achieved by introducing flexible PDMS chains during the curing process resulting to a hybrid elastomer networks. This kind of soft but robust materials can find several applications in diverse fields, such as soft robotics, flexible, and stretchable electronics.     

Infections and Immunotherapy in Lung Cancer: A Bad Relationship?

Infectious diseases represent a relevant issue in lung cancer patients. Bacterial and viral infections might influence the patients’ prognosis, both directly affecting the immune system and indirectly impairing the outcome of anticancer treatments, mainly immunotherapy. In this analysis, we aimed to review the current evidence in order to clarify the complex correlation between infections and lung cancer. In detail, we mainly explored the potential impact on immunotherapy outcome/safety of (1) bacterial infections, with a detailed focus on antibiotics; and (2) viral infections, discriminating among (a) human immune-deficiency virus (HIV), (b) hepatitis B/C virus (HBV-HCV), and (c) Sars-Cov-2. A series of studies suggested the prognostic impact of antibiotic therapy administration, timing, and exposure ratio in patients treated with immune checkpoint inhibitors, probably through an antibiotic-related microbiota dysbiosis. Although cancer patients with HIV, HBV, and HCV were usually excluded from clinical trials evaluating immunotherapy, some retrospective and prospective trials performed in these patient subgroups reported similar results compared to those described in not-infected patients, with a favorable safety profile. Moreover, patients with thoracic cancers are particularly at risk of COVID-19 severe outcomes and mortality. Few reports speculated about the prognostic implications of anticancer therapy, including immunotherapy, in lung cancer patients with concomitant Sars-Cov-2 infection, showing, to date, inconsistent results. The correlation between infectious diseases and immunotherapy remains to be further explored and clarified in the context of dedicated trials. In clinical practice, the accurate and prompt multidisciplinary management of lung cancer patients with infections should be encouraged in order to select the best treatment options for these patients, avoiding unexpected toxicities, while maintaining the anticancer effect.